NCT06529796View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions

Focal Segmental Glomerulosclerosis (FSGS)

Interventions

DRUG

IXP

Tablet for oral administration.

Trial Locations (3)

33136

Division of Clinical Pharmacology, University of Miami, Miami

33705

GCP Research, St. Petersburg

78215

Texas Liver Institute, San Antonio

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06529796 - Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter